Lung Cancer
Volume 68, Issue 3 , Pages 403-408 , June 2010

The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer

Received 11 May 2009 ,Revised 29 September 2009 ,Accepted 1 October 2009.

References 

  1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARC Press; 2001;
  2. Ponn RB, Lo Cicero J, Daly BDT. Surgical treatment of non-small cell lung cancer. In:  Shields TW,  Lo Cicero J,  Ponn R, et al. editor. General thoracic surgery. 6th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 1548–1587
  3. Mountain CF. Revisions in the International System for staging lung cancer. Chest. 1997;111:1710–1717
  4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909
  5. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  6. Douillard JY, Rosell R, Delena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727
  7. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  8. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–182
  9. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95:1453–1461
  10. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–3559
  11. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852–3859
  12. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–857
  13. Fossella F, Pereira J, van Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003;21:3016–3024
  14. Belani CP, Einzig A, Bonomi P, et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-smallcell lung cancer. Ann Oncol. 2000;11:673–678
  15. Wang SY, Ye X, Ou W, et al. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer. 2009;64:238–243
  16. Calvert A, Newell D, Gumbrell L, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Onco. 1989;17:1748–1756
  17. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0. DCTD, NCI, NIH, DHHS; March 31, 2003 [Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf].
  18. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–5051
  19. Wang Siyu, Ou Wei, Lin Yongbin, et al. A prospective randomized study of adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer. Chin J Cancer Res. 2007;19:189–195
  20. Stinchcombe TE, Harper HD, Hensing TA, et al. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008;3:145–151
  21. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and Intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005;47:385–394
  22. Gridelli c , Maione P, Comunale D, et al. Adjuvant chemotherapy in elderly patients with non-small cell lung cancer. Cancer Control. 2007;14:57–62
  23. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173–181
  24. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol. 2003;22:639;[abstr 2571]
  25. Kelly K, Giarritta S, Hayes S, et al. Should older patients (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLS)? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol. 2001;20:329;[abstr 1313]
  26. Belani CP, Fossella FV. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin vs vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Lung Cancer. 2003;41(Suppl. 2):S18
  27. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent vs combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005;23:190–196
  28. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003;98:779–788
  29. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007;25:1553–1561
  30. Feliu J, Martin G, Madronal C, et al. Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced nonsmall-cell lung cancer. Cancer Chemother Pharmacol. 2003;52:247–252
  31. Maestu I, Gomez-Aldaravi L, Torregrosa MD, et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced nonsmall cell lung cancer. Lung Cancer. 2003;42:345–354
  32. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based practice guideline. J Clin Oncol. 2006;24:3187–3205
  33. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5:188–202

PII: S0169-5002(09)00501-7

doi: 10.1016/j.lungcan.2009.10.002

Lung Cancer
Volume 68, Issue 3 , Pages 403-408 , June 2010

Article Tools